Rezolute is developing drug therapies to cure patients with metabolic diseases associated with chronic glucose imbalance. Both extreme low (hypoglycaemia) and high (hyperglycaemia) blood glucose levels cause disease. Rezolute is developing antibody-based therapies to treat patients with congenital hyperinsulinism (HI), diabetic macular edema and tumor HI. Their approach is to leverage their metabolic expertise to define disease pathways and create therapies that overcome the shortcomings of current standards of care. Rezolute’s lead program, RZ358, is in late-stage clinical trials for congenital HI.

Rezolute

Founded: 2010
Location: Redwood City, CA
Employee range: 11 - 50
Clinical stage: Clin3
Therapy area: Congenital hyperinsulinism
Drug types: RAR, END, GEN, OPH
Lead product: RZ358
Funding: $122M stock Apr 2022; $55M stock Oct 2021; $20M stock Jul 2019

Drug notes:

About:

Jobs: